Synergistic promoting effects of pentoxifylline and simvastatin on the apoptosis of triple-negative MDA-MB-231 breast cancer cells

  • Authors:
    • Yessica Cristina Castellanos-Esparza
    • Shuang Wu
    • Limin Huang
    • Catherine Buquet
    • Rong Shen
    • Berenice Sanchez-Gonzalez
    • Ethel Awilda García Latorre
    • Olivier Boyer
    • Remi Varin
    • Luis Antonio Jiménez-Zamudio
    • Anne Janin
    • Jean-Pierre Vannier
    • Hong Li
    • He Lu
  • View Affiliations

  • Published online on: February 9, 2018     https://doi.org/10.3892/ijo.2018.4272
  • Pages:1246-1254
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Pentoxifylline (PTX), a xanthine family molecule and simvastatin (SIM), an anti-hypercholesterolemic agent, have recently been considered as sensitizers to chemotherapy and radiotherapy. The present in vitro study evaluated their antitumor synergistic effects on MDA‑MB‑231 breast cancer cells characterized by the triple‑negative phenotype (TNP). The anti-proliferative effects of these two agents were evaluated by MTT and clonogenic assays. Cell cycle progression was examined using propidium iodide staining. Apoptosis was investigated by Annexin V labeling, and by examining caspase 3 activity and DNA fragmentation. Autophagic vesicles and reactive oxygen species (ROS) levels were monitored by flow cytometry. Western blot analysis was performed to evaluate molecular targets. Our results revealed that when used alone, PTX and SIM exerted antitumor effects. Nevertheless, used in combination, the inhibition of cell proliferation was synergistically superior (80% vs 42%) than that observed following treatment with each agent alone after 48 h. PTX alone (0.5 mM) induced both apoptosis (25%) and autophagy (25%); however, when used in combination with SIM (0.5 µM), the balance between these processes was disrupted and the cells underwent apoptosis (>65%) as opposed to autophagy (<13%). This imbalance was associated with an increase in ERK1/2 and AKT activation, but not with an increase in mTOR phosphorylation, and with the suppression of the NF-κB pathway. In addition, in the cells treated with both agents, almost 78% of the cells were arrested at the G0/G1 phase and lost their colony-forming ability (38±5%) compared to the cells treated with PTX alone (115±5%). On the whole, these results suggest that the induction of autophagy may be a protective mechanism preventing MDA‑MB‑231 cancer cell death. The combined use of PTX and SIM may drive dormant autophagic cancer cells to undergo apoptosis and thus this may be a novel treatment strategy for breast cancer characterized by the TNP.

Related Articles

Journal Cover

April 2018
Volume 52 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

2016 Impact Factor: 3.079
Ranked #33/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Castellanos-Esparza, Y.C., Wu, S., Huang, L., Buquet, C., Shen, R., Sanchez-Gonzalez, B. ... Lu, H. (2018). Synergistic promoting effects of pentoxifylline and simvastatin on the apoptosis of triple-negative MDA-MB-231 breast cancer cells. International Journal of Oncology, 52, 1246-1254. https://doi.org/10.3892/ijo.2018.4272
MLA
Castellanos-Esparza, Y. C., Wu, S., Huang, L., Buquet, C., Shen, R., Sanchez-Gonzalez, B., García Latorre, E. A., Boyer, O., Varin, R., Jiménez-Zamudio, L. A., Janin, A., Vannier, J., Li, H., Lu, H."Synergistic promoting effects of pentoxifylline and simvastatin on the apoptosis of triple-negative MDA-MB-231 breast cancer cells". International Journal of Oncology 52.4 (2018): 1246-1254.
Chicago
Castellanos-Esparza, Y. C., Wu, S., Huang, L., Buquet, C., Shen, R., Sanchez-Gonzalez, B., García Latorre, E. A., Boyer, O., Varin, R., Jiménez-Zamudio, L. A., Janin, A., Vannier, J., Li, H., Lu, H."Synergistic promoting effects of pentoxifylline and simvastatin on the apoptosis of triple-negative MDA-MB-231 breast cancer cells". International Journal of Oncology 52, no. 4 (2018): 1246-1254. https://doi.org/10.3892/ijo.2018.4272